Form 4: Pacira Director Sells 500 Shares of Common Stock

Pacira BioSciences, Inc. Director Mark Froimson sold 500 shares of the company's common stock at $21.81 per share.

Summary

• Mark Froimson, a Director of Pacira BioSciences, Inc. (PCRX), disposed of 500 shares of common stock.
• The transaction occurred on March 17, 2026, at a price of $21.81 per share.
• Following this transaction, Mr. Froimson directly beneficially owns 20,136 shares of Pacira BioSciences, Inc. common stock.
• The sale was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale of 500 shares by a director, especially under a pre-arranged 10b5-1 plan, is a routine insider transaction and does not typically reflect a change in the company's prospects.

Negatives

• A Director, Mark Froimson, sold 500 shares of common stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales executed under a Rule 10b5-1 plan, are common for personal financial planning, diversification, or liquidity needs and do not inherently signal a change in the company's operational outlook or fundamental value. The relatively small volume of shares sold in this instance is typical for such routine transactions.

Stakeholder Impact

• Shareholders: Minimal impact due to the small volume of shares sold by a director, likely for personal financial planning rather than a reflection of company performance.

Key Dates

Recommendation

The transaction reported is a routine insider sale of a relatively small number of shares by a director, likely executed under a Rule 10b5-1 plan. This type of transaction typically does not indicate a shift in the company's fundamental performance or future prospects, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Pacira BioSciences, PCRX, Insider Trading, Form 4, Stock Sale, Director, Mark Froimson, 10b5-1 Plan